Physician profile
Simona Denkovski
NPI 1699496398
$10,847.98
in general payments reported to CMS, 2019-2025
25 companies · $4,200 in 2025
The $4,200 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $163 · 2023: $3,422 · 2024: $3,063 · 2025: $4,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,336.79 |
| Education | $347.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,528.58 | 2022-2025 | Krystexxa, Enbrel, Tavneos |
| Abbvie INC. | $1,769.58 | 2022-2025 | |
| Janssen Biotech, INC. | $1,593.71 | 2023-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $902.14 | 2023-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $806.49 | 2022-2025 | |
| Lilly USA, LLC | $537.19 | 2022-2024 | Taltz |
| Pfizer INC. | $493.45 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $301.44 | 2024-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $225.14 | 2022-2025 | Benlysta |
| Genzyme Corporation | $214.48 | 2024-2025 | |
| Horizon Therapeutics Plc | $190.33 | 2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $180.01 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $170.42 | 2024-2025 | Orencia |
| Fresenius Kabi USA, LLC | $159.61 | 2023-2025 | Tyenne, Idacio |
| Aurinia Pharma U.S., INC. | $139.77 | 2023-2025 | Lupkynis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $135.91 | 2023-2025 | Hadlima, Renflexis |
| Kiniksa Pharmaceuticals, LTD. | $116.39 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $102.13 | 2024 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $93.57 | 2022-2025 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $75.09 | 2024-2025 | Saphnelo |
| Genentech USA, INC. | $28.91 | 2025 | Gazyva |
| Radius Health, INC. | $25.19 | 2023 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $23.19 | 2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.43 | 2023 | Cyltezo |
| Hikma Pharmaceuticals USA | $16.83 | 2023 | Mitigare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simona Denkovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.